InvestorsHub Logo
Followers 2
Posts 113
Boards Moderated 0
Alias Born 10/05/2018

Re: BluePineCapital post# 23376

Tuesday, 01/29/2019 12:44:50 PM

Tuesday, January 29, 2019 12:44:50 PM

Post# of 32923
Agreed.

Great points.

Medical side is the main reason I invested here.

Also curious as to where they stand with GNBT and their RapidMist technology:

I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (OTCQB: GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be relized value.


Also on their extraction franchise they are supposed to start marketing in February (how many interested, revenue, time, etc.)